PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p

PD-L1 is expressed by a subset of patients with metastatic melanoma (MM) with an unfavorable outcome. Its expression is increased in cells resistant to BRAF or MEK inhibitors (BRAFi or MEKi). However, the function and regulation of expression of PD-L1 remain incompletely understood. After generating...

Descripción completa

Detalles Bibliográficos
Autores principales: Audrito, Valentina, Serra, Sara, Stingi, Aureliano, Orso, Francesca, Gaudino, Federica, Bologna, Cinzia, Neri, Francesco, Garaffo, Giulia, Nassini, Romina, Baroni, Gianna, Rulli, Eliana, Massi, Daniela, Oliviero, Salvatore, Piva, Roberto, Taverna, Daniela, Mandalà, Mario, Deaglio, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362532/
https://www.ncbi.nlm.nih.gov/pubmed/28199980
http://dx.doi.org/10.18632/oncotarget.15213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362532/
https://www.ncbi.nlm.nih.gov/pubmed/28199980
http://dx.doi.org/10.18632/oncotarget.15213

Ejemplares similares